Each year, nearly 14 million people in the U.S. contract human papillomavirus, a common, sexually-transmitted virus that can cause several cancers.
A recent study led by researchers at the University of Arizona Cancer Center and Northern Arizona University found that Native American women were disproportionately affected by vaginal dysbiosis, a disruption in the balance of bacterial that increases the risk of human papillomavirus infection, which can cause cervical cancer.
Clinical and real-world data for the 9-valent human papillomavirus vaccine, Gardasil 9, evaluating the burden and incidence of certain HPV-related cancers and diseases, were presented at the International Papillomavirus Conference 2024 in Edinburgh, UK, from Nov. 12-15.
The American Society for Radiation Oncology published an updated clinical guideline in Practical Radiation Oncology that details best practices for using radiation therapy to treat patients who have oropharyngeal squamous cell carcinoma caused by the human papilloma virus.
In an era of intensifying judicial repudiation of evidence-based guidelines and deepening public mistrust toward science, America’s screening rate for cervical cancer has been declining.
St. Jude’s Path to a Bright Future, an HPV awareness and vaccination campaign with nearly 160 partners, is aimed at reducing that disease burden by targeting children in a crucial age range.
The standard of care in HPV vaccination may soon change if a one-dose regimen is found to be just as efficacious as two or three doses—once a large trial that NCI is conducting in Costa Rica, in young women ages 12 to 16, is ready to report final results in a few years. “We’ve done […]
